XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value Nov 07, 2023 7:30am EST
XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG) Oct 31, 2023 7:30am EDT
XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy Aug 08, 2023 7:30am EDT
XOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology Asset Jun 22, 2023 7:30am EDT
XOMA Reports First Quarter 2023 Financial Results and Provides Update on the Acceleration of its Differentiated Royalty Monetization Strategy May 09, 2023 7:30am EDT
